Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.77)
# 106
Out of 5,124 analysts
48
Total ratings
66.67%
Success rate
40.72%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRXS NeurAxis | Maintains: Buy | $7 → $8 | $4.41 | +81.41% | 2 | Dec 22, 2025 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $54.80 | +16.79% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $36.25 | -6.21% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.50 | +86.67% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.50 | +189.21% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.09 | +55.15% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $8.54 | +28.81% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.87 | -22.48% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $15.83 | +7.39% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $16.73 | +67.36% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $18.48 | +111.04% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.59 | +74.29% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.26 | +104.68% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $5.57 | +7.82% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.33 | +89.57% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $7.95 | +25.79% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $21.50 | +6.98% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.71 | +69.01% | 2 | Jul 11, 2023 |
NeurAxis
Dec 22, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.41
Upside: +81.41%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $54.80
Upside: +16.79%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $36.25
Upside: -6.21%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.50
Upside: +86.67%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.50
Upside: +189.21%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.09
Upside: +55.15%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $8.54
Upside: +28.81%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.87
Upside: -22.48%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $15.83
Upside: +7.39%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $16.73
Upside: +67.36%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.48
Upside: +111.04%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.59
Upside: +74.29%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.26
Upside: +104.68%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $5.57
Upside: +7.82%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.33
Upside: +89.57%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $7.95
Upside: +25.79%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $21.50
Upside: +6.98%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.71
Upside: +69.01%